Indian Pharma Firms to Benefit from UK NHS Procurement Plan

New Delhi, Jul 26 (KNN) Indian pharmaceutical companies will now have access to the UK's National Health Service (NHS) procurement strategy, following a recent update under the India-UK Enhanced Trade Partnership. 

This move is expected to provide Indian drug manufacturers with better insight into upcoming procurement opportunities in the UK’s healthcare system.

The NHS, which is one of the world’s largest publicly funded healthcare systems, spends around Euro 393 million (approximately Rs 4,200 crore) on pharmaceutical imports annually. 

Indian pharma companies are already key suppliers of generic drugs and are likely to gain further ground with this increased transparency.

According to the UK government, sharing details of the NHS procurement plan will help improve predictability and planning for Indian companies, potentially leading to better pricing, timely deliveries, and a stronger supplier relationship. 

This development is being seen as part of the broader effort to deepen trade and investment ties between India and the UK, particularly in sectors like pharmaceuticals and healthcare.

The Department for Business and Trade (DBT) of the UK stated that the move aligns with the goal of ensuring consistent and cost-effective access to high-quality medicines. 

It could also contribute to reducing the NHS's procurement costs in the long term, benefiting both suppliers and patients.

This announcement comes ahead of the anticipated Free Trade Agreement (FTA) between India and the UK, where pharmaceuticals and healthcare are expected to be major areas of collaboration. 

Indian industry experts have welcomed the step, stating that better access to NHS planning documents would enhance long-term strategic engagement between the two nations in the healthcare domain.

(KNN Bureau)